2025 ACMT Psychedelics Seminar
Includes Multiple Live Events. The next is on 10/10/2025 at 10:00 AM (EDT)
-
Register
- Non-member - Tier I - $450
- Non-member - Tier II - $400
- Non-member - Tier III - $350
- Non-member - Tier IV - $300
- Member - Tier I - $350
- Member - Tier II - $300
- Member - Tier III - $250
- Member - Tier IV - $200
ACMT Psychedelics Seminar
Fridays in October 2025: 10/10 & 10/17
10-3:45pm ET, Virtual Course, Live Zoom Event
Explore the evolving science, clinical applications, and complex realities of psychedelics in the 2025 ACMT Psychedelics Seminar, a two-day virtual course designed for healthcare professionals, clinicians, and toxicologists.
Held over two Fridays in October, this immersive course provides a comprehensive foundation in the pharmacology, toxicology, and therapeutic uses of psychedelics, while critically examining their place in today’s healthcare landscape.
Course Themes:
- Psychedelics 101: Pharmacology & Foundations
- Clinical Applications
- Adverse Effects & Safety
- Policy, Ethics & Real-World Implementation
Over two days, participants will explore the pharmacology of classic psychedelics—including psilocybin, ayahuasca, mescaline, and LSD—as well as the therapeutic potential of ketamine, ibogaine, MDMA, and other novel psychotherapies. The course will review current evidence on psychedelics for treating substance use disorders, depression, PTSD, anxiety, and emerging areas such as dementia and Parkinson’s disease. Sessions will address the shifting legal and regulatory landscape, highlighting lessons from Oregon and Colorado’s psilocybin programs, the rapid growth of ketamine clinics, and the realities of microdosing.
Throughout the seminar, faculty will emphasize safety, adverse effects, drug interactions, and emerging designer substances, while engaging participants in critical conversations about indigenous knowledge, ethical access, and responsible integration of psychedelics into modern healthcare.
Registration for this activity includes two-days of live virtual event programming, 90 day access to the on-demand recordings after the live event, and 10.0 Continuing Education credits.
Target Audience
This seminar is designed for healthcare professionals and researchers interested in medical toxicology, addiction medicine and the emerging role of psychedelics in therapeutic settings, including:
- Physicians
- Pharmacists
- Nurses and Nurse Practitioners
- Physician Assistants
- Clinicians and Specialists in Poison Information
- Addiction Counselors and Mental Health Professionals
- Researchers
- Fellows, Residents, and Students
Continuing Education
Live and Enduring continuing education credits for Physicians, Pharmacists, and Nurses is provided by AKH Inc., Advancing Knowledge in Healthcare. It is expected that learners will receive up to 10.0 credits for learning and change.
Learner Objectives
After Completing This Program You Should Be Able To:
- Describe the pharmacology and toxicology of classic and emerging psychedelics, including psilocybin, ketamine, ibogaine, and MDMA.
- Evaluate current research on the clinical use of psychedelics in treating substance use disorders, mental health conditions, palliative care, and special populations.
- Analyze the adverse effects and safety considerations associated with psychedelic use.
- Identify practical strategies, legal factors, ethical considerations, and systemic barriers to integrating psychedelic-assisted therapies into existing treatment frameworks.
Questions?
Please write to ACMT at events@acmt.net
Registration Rates
Registration includes:
- Access to the live virtual events on October 10, 2025 and October 17, 2025
- Access to the on-demand recording for 90 days after the live virtual events
- Access to the speaker slides
- 10.0 Continuing Education credits for Physicians (CME), Pharmacists (CPE) or Nurses (CNE)
Member Rates
Member Tier I: Full, Affiliate, International, Emeritus |
$350 |
Member Tier II: Fellows |
$300 |
Member Tier III: Residents, International - Developing Country |
$250 |
Member IV: Medical Students |
$200 |
Non-Member Rates
Non-member Tier I: Physicians, Pharmacists, Lawyers, "Other" |
$450 |
Non-member Tier II: Fellows, SPIs, Nurses, etc. |
$400 |
Non-member Tier III: Educators & Emergency Responders |
$350 |
Non-member IV: Residents & Students |
$300 |
ACMT Membership
ACMT Members receive a discounted rate. Interested in becoming an ACMT Member? Contact our Membership Team at membership@acmt.net. Learn more at: www.acmt.net/membership
Refunds and Cancellations
For information on ACMT's Cancellation and refund policy, click here.
Questions?
For any questions, please email us at events@acmt.net.
This agenda is preliminary and subject to change. Speakers will be added as they confirm their participation. For the convenience of attendees from around the country, all times zones are listed -- please make sure you are looking at your correct time zone.
Friday, October 10, 2025
7:00-7:15 AM PT | 8:00-8:15 AM MT | 9:00-9:15 AM CT | 10:00-10:15 AM ET
Welcome & Opening Remarks
7:15-8:15 AM PT | 8:15-9:15 AM MT | 9:15-10:15 AM CT | 10:15-11:15 AM ET
Classic Psychedelics (Psilocybin, Ayahuasca, Mescaline & LSD) and Beyond (Ketamine, Ibogaine, MDMA & Novel Psychotherapies)
Joshua Woolley, MD, PhD, Associate Professor of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco
8:15-9:15 AM PT | 9:15-10:15 AM MT | 10:15-11:15 AM CT | 11:15-12:15 PM ET
Treating Substance Use Disorders: Emerging Evidence and Approaches
9:15-9:30 AM PT | 10:15-10:30 AM MT | 11:15-11:30 AM CT | 12:15-12:30 PM ET
Break
9:30-10:30 AM PT | 10:30-11:30 AM MT | 11:30-12:30 PM CT | 12:30-1:30 PM ET
Mental Health Breakthroughs: Psychedelics in Depression, PTSD & Anxiety
10:30-11:00 AM PT | 11:30-12:00 PM MT | 12:30-1:00 PM CT | 1:30-2:00 PM ET
Psychedelics and the Management of Acute Suicidal Ideation
Anthony F. Pizon, MD, Chief, Division of Medical Toxicology, Department of Emergency Medicine, Professor, University of Pittsburgh School of Medicine
11:00-11:15 AM PT | 12:00-12:15 PM MT | 1:00-1:15 PM CT | 2:00-2:15 PM ET
Break
11:15-11:45 AM PT | 12:15-12:45 PM MT | 1:15-1:45 PM CT | 2:15-2:45 PM ET
Psychedelics & Neurodegeneration
Albert Garcia-Romeu, PhD, Associate Professor, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
11:45-12:15 PM PT | 12:45-1:15 PM MT | 1:45-12:15 PM CT | 2:45-3:15 PM ET
At Life's Edge: Psychedelic Use in Palliative and End-of-Life Care
Benjamin Hatten, MD, MPH, Medical Toxicologist, Toxicology Associates & Associate Professor of Emergency Medicine, University of Colorado
12:15-12:45 PM PT | 1:15-1:45 PM MT | 2:15-2:45 PM CT | 3:15-3:45 PM ET
Advancing Psychedelic Science: Novel Molecules, New Mechanisms
Alex Kwan, PhD, Associate Professor, Meinig School of Biomedical Engineering, Cornell University
Friday, October 17, 2025
7:00-7:15 AM PT | 8:00-8:15 AM MT | 9:00-9:15 AM CT | 10:00-10:15 AM ET
Welcome & Opening Remarks
7:15-8:00 AM PT | 8:15-9:00 AM MT | 9:15-10:00 AM CT | 10:15-11:00 AM ET
Proceed with Caution: Adverse Effects, Drug Interactions & Designer Psychedelics
Shana Kusin, MD, Associate Professor of Emergency Medicine, Oregon Health & Science University
8:00-8:45 AM PT | 9:00-9:45 AM MT | 10:00-10:45 AM CT | 11:00-11:45 AM ET
The Wild West of Ketamine: Safety and Health Equity Concerns Surrounding the Use of Ketamine for Psychiatric Conditions
Arielle Graham, MD, Associate Psychiatrist, Brigham and Women’s Hospital; Instructor, Harvard Medical School
Powell Graham, MD, Assistant Professor of Emergency Medicine, UMass Chan Medical School; Director of Outpatient Toxicology Services, UMass Memorial Health
Jeffrey Lai, MD, Assistant Professor and Fellowship Director, UMass Chan Medical School
8:45-9:30 AM PT | 9:45-10:30 AM MT | 10:45-11:30 AM CT | 11:45-12:30 PM ET
Microdosing and the Mainstream: Real-World Use Beyond the Hype
Sandeep Nayak, MD, Psychiatrist, Assistant Professor, Center for Psychedelic and Consciousness Research, Johns Hopkins
9:30-9:45 AM PT | 10:30-10:45 AM MT | 11:30-11:45 AM CT | 12:30-12:45 PM ET
Break
9:45-10:15 AM PT | 10:45-11:15 AM MT | 11:45-12:15 PM CT | 12:45-1:15 PM ET
The Legal Landscape: Psychedelics in Policy and Practice Today
Mason Marks, MD, JD, Florida Bar Health Law Section Professor, Florida State University
10:15-10:45 AM PT | 11:15-11:45 AM MT | 12:15-12:45 PM CT | 1:15-1:45 PM ET
Regulatory Realities: Navigating FDA Approval and DEA Scheduling of Psychedelics
10:45-11:30 AM PT | 11:45-12:30 PM MT | 12:45-1:30 PM CT | 1:45-2:30 PM ET
Indigenous Knowledge & Ethical Access: Rights, Reciprocity & Respect
11:30-11:45 AM PT | 12:30-12:45 PM MT | 1:30-1:45 PM CT | 2:30-2:45 PM ET
Break
11:45-12:45 PM PT | 12:45-1:45 PM MT | 1:45-2:45 PM CT | 2:45-3:45 PM ET
The Oregon & Colorado Models: Lessons from the First State-Regulated Psilocybin Markets
Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT (Moderator)
Emergency Medicine Attending Physician, Professor Of Emergency Medicine, Co-Medical Director
MedStar Washington Hospital Center, Georgetown University Hospital, National Capital Poison Center
Dr. Maryann Amirshahi is a Professor of Emergency Medicine at Georgetown University School of Medicine and practices clinically at MedStar Washington Hospital Center, where she specializes in toxicology, addiction care, and emergency medicine. She holds a PharmD and medical degree, alongside an MPH focusing on environmental and occupational health, and a PhD in pharmacology and public health. Dr. Amirshahi is board-certified in emergency medicine, medical toxicology, addiction medicine, and clinical pharmacology, and is a registered pharmacist with over a decade of practice. Nationally recognized, she serves on the Board of Directors for the American College of Medical Toxicology and as co-medical director of the National Capital Poison Center. With nearly 200 peer-reviewed publications, her research spans medication safety, drug shortages, addiction treatment, and prescription drug misuse.
Albert Garcia-Romeu, PhD
Associate Professor, Behavioral Pharmacology Research Unit
Johns Hopkins University
Albert Garcia-Romeu, PhD, is an Associate Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. His research examines the effects of psychedelics in humans, with a focus on psilocybin as an aid in the treatment of addiction. His current research interests include clinical applications of psychedelics, real-world drug use patterns, diversity in science, and the role of spirituality in mental health. He is a founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research and the International Society for Research on Psychedelics. He serves on the Board of Directors for the College on Problems of Drug Dependence (CPDD) and is an Associate Editor for the journal Psychedelic Medicine.
Arielle Graham, MD
Associate Psychiatrist & Instructor
Brigham and Women’s Hospital & Harvard Medical School
Dr. Graham is double board-certified (adult and child/adolescent) psychiatrist with expertise in young adult mental health, emergency mental health, consultation-liaison psychiatry, medical education/training, clinical informatics and medical writing/editing. She completed her psychiatry residency and child and adolescent psychiatry fellowship at UMass Chan Medical School, following which she worked as an attending psychiatrist at UMass Memorial Medical Center and an Assistant Professor of Psychiatry and Pediatrics at UMass Chan Medical School. She is currently an Associate Psychiatrist at Brigham and Women’s Hospital and a Clinical Instructor in Psychiatry at Harvard Medical School.
Powell Graham, MD
Assistant Professor of Emergency Medicine
University of Massachusetts Chan Medical School
Dr. Graham works as a board-certified medical toxicologist and an emergency medicine physician at UMass Chan Medical School in Worcester, MA. There, he is also the director of the outpatient toxicology clinic. He acts as an educator, clinician, and researcher in these capacities. He completed his toxicology fellowship in 2022 at UMass after completing his residency in emergency medicine also at UMass. His current academic and research interests include psychedelics, addiction medicine, cannabinoids, and harm reduction.
Benjamin Hatten, MD, MPH
Medical Toxicologist, Toxicology Associates & Associate Professor of Emergency Medicine
University of Colorado
Dr. Ben Hatten is an Assistant Professor in the Department of Emergency Medicine at the University of Colorado School of Medicine, with a primary appointment in the Section of Medical Toxicology. He is also an attending physician at the Rocky Mountain Poison and Drug Center and serves as faculty for the Emergency Medicine Residency, Occupational Medicine Residency, and Medical Toxicology Fellowship programs in Denver. Board certified in both emergency medicine and medical toxicology, Dr. Hatten actively practices in both fields. He earned his M.D. from the University of Texas Southwestern Medical Center and completed his emergency medicine residency at Denver Health Medical Center. He went on to complete a Medical Toxicology Fellowship at Oregon Health & Science University, where he also earned an M.P.H. in epidemiology and biostatistics. Since returning to Denver in 2013, he has been a key contributor to toxicology education, research, and clinical care across multiple institutions.
Robert Hendrickson, MD, FACMT (Moderator)
Professor of Emergency Medicine, Medical Director, Program Director
Oregon Health and Science University, Oregon Poison Center, OHSU Fellowship in Medical Toxicology
Dr. Rob Hendrickson graduated from the State University of New York, Downstate College of Medicine, and completed training in Emergency Medicine and Medical Toxicology at the Medical College of Pennsylvania. He is a Professor of Emergency Medicine at Oregon Health and Sciences University where he is Chief of the Section of Medical Toxicology, Program Director for the fellowship in medical toxicology, and the Medical Director of the Oregon Poison Center.
Shana Kusin, MD, FACMT (Moderator)
Associate Professor of Emergency Medicine
Oregon Health & Science University
Dr. Shana Kusin is an Associate Professor of Emergency Medicine at Oregon Health & Science University (OHSU), where she has served as full-time faculty since 2013 following her fellowship in Medical Toxicology at OHSU and the Oregon Poison Center. She sees patients in both the OHSU and Doernbecher Emergency Departments. Dr. Kusin’s academic interests center on medical toxicology—particularly drugs of abuse and plant- and animal-based toxins—as well as leveraging electronic health records to improve community-wide healthcare through information sharing and clinical decision support.
Alex Kwan, PhD
Associate Professor, Meinig School of Biomedical Engineering
Cornell University
Dr. Alex Kwan is a neuroscientist and Associate Professor at Cornell University, where he leads a research lab focused on uncovering how psychiatric drugs affect brain function and behavior. He earned his Ph.D. in applied physics from Cornell and completed postdoctoral training in neuroscience at UC Berkeley. Before returning to Cornell in 2022, he was a faculty member in the Department of Psychiatry at Yale School of Medicine. Dr. Kwan’s lab combines systems neuroscience, optical imaging, and behavioral paradigms in animal models to study how compounds like ketamine and serotonergic psychedelics alter neural circuits to produce therapeutic effects. His long-term goal is to develop effective and safe treatments for depression by leveraging neurobiological insights into drug action.
Jeffrey Lai, MD
Assistant Professor and Director, Medical Toxicology Fellowship
UMass Chan Medical School
Jeffrey Lai, MD, is an emergency physician and medical toxicologist. He completed his undergraduate studies at the University of California, Berkeley; medical school at the University of Pittsburgh; and emergency medicine residency and medical toxicology fellowship at the University of Massachusetts. He is the program director of the medical toxicology fellowship at UMass Chan Medical School, and his academic interests include medical education, the application of novel technologies to the treatment of substance use disorders, and the surveillance of impairing substances in patients with severe traumatic injurie
Sandeep Nayak, MD
Psychiatrist, Assistant Professor, Center for Psychedelic and Consciousness Research
Johns Hopkins University
Dr. Sandeep Nayak is a psychiatrist and Assistant Professor at the Center for Psychedelic and Consciousness Research at Johns Hopkins University. He earned his medical degree from Brown University and completed his psychiatry residency at Johns Hopkins Hospital. His research focuses on the use of psychedelics to treat psychiatric conditions, particularly substance use and mood disorders, with additional interests in psychedelic-induced belief change and the application of Bayesian statistics to clinical trials. In addition to his research, Dr. Nayak provides clinical care at Addiction Treatment Services (ATS) and the Center for Addiction and Pregnancy (CAP) at Johns Hopkins Bayview Medical Center.
Mason Marks, MD, JD
Florida Bar Health Law Section Professor
Florida State University
Dr. Mason Marks is the Florida Bar Health Law Section Professor at Florida State University College of Law and a leading expert on drug policy, health law, and the regulation of psychedelics. He is a Senior Fellow at Harvard Law School’s Petrie-Flom Center, where he co-founded and directs the Project on Psychedelics Law and Regulation (POPLAR), and a Visiting Fellow at Yale Law School’s Information Society Project. With dual degrees in medicine and law, Dr. Marks publishes widely on drug regulation, constitutional rights, and the intersection of AI, health, and free thought, with scholarship appearing in top law reviews and medical journals such as JAMA, Nature Medicine, and The New England Journal of Medicine. His work has been cited by the U.S. Court of Appeals, the U.S. Senate, the WHO, and the FTC, and featured in major media outlets including The New York Times, NPR, and The Economist. A sought-after speaker and advisor, Dr. Marks regularly briefs state and federal agencies on controlled substances policy and teaches courses on constitutional, administrative, health, and psychedelic law. He holds degrees from Amherst College (BA), Tufts University (MD), and Vanderbilt University (JD).
Anthony Pizon, MD, FACMT
Chief of Medical Toxicology Division, Professor of Emergency Medicine
University of Pittsburgh
Dr. Anthony (Tony) Pizon received his medical degree from the University of Toledo School of Medicine in 2001. He then completed his Emergency Medicine Residency at the University of Pittsburgh Medical Center in 2004 and his Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, Arizona in 2006. Dr. Pizon is currently a Professor in the Department of Emergency Medicine, Division of Medical Toxicology at the University of Pittsburgh, School of Medicine. He serves as Chief of the Division of Medical Toxicology and Director of the Medical Toxicology Fellowship at UPMC. He is also Assistant Medical Director of both the Pittsburgh and West Virginia Poison Centers. Yet, most importantly, he is blessed with amazing wife, Caryn, and four wonderful children (Benjamin, Elizabeth, Gabriela, and Seraphina).
Evan Schwarz, MD, FACMT (Moderator)
Associate Professor of Emergency Medicine
University of California, Los Angeles
Dr. Evan Schwarz attended medical school at the University of Texas Medical Branch in Galveston, Texas, before completing a residency in Emergency Medicine at the Washington University School of Medicine in Saint Louis, Missouri. After residency, he completed a fellowship in Medical Toxicology at the University of Texas Southwestern School of Medicine in Dallas, Texas, before returning to Missouri where he was an Advisory Dean and the Medical Toxicology Division Chief and Fellowship Director at Washington University. In 2023, he took a position in the Department of Emergency Medicine at the University of California Los Angeles. He is also a member of the Board of Directors for ACMT.
Joshua Woolley, MD, PhD
Associate Professor of Psychiatry, UCSF Weill Institute for Neurosciences
University of California, San Francisco
Dr. Josh Woolley is a nationally recognized leader in psychedelic science and psychiatric research. He serves as Associate Professor of Psychiatry at UCSF and Director of the Translational Psychedelic Research (TrPR) Program, where he leads groundbreaking studies on the safety, efficacy, and therapeutic mechanisms of compounds such as psilocybin, MDMA, and ketamine for treating neuropsychiatric disorders. A board-certified psychiatrist and staff physician at the San Francisco VA, Dr. Woolley also serves as Associate Director of its Psychosis Clinic and has played a key role in training the next generation of clinicians and researchers. He has mentored over 30 postdocs and 8 junior faculty, co-directed UCSF’s foundational psychiatry course, and earned multiple accolades for his excellence in teaching and research. His work is supported by the VA, Department of Defense, philanthropic foundations, and industry, and has been published in top-tier journals including JAMA, Nature Neuroscience, and Biological Psychiatry.
Instructions
Once you have completed your registration:
- Click on the Contents tab and attend the live events.
- Complete the Post-Test. These questions are based on content from the lectures to gauge your comprehension. It requires a 80% to pass.
- Complete the CE Survey. These questions are required to claim your CE certificate.
- Claim your CE certificate. Once you have claimed your CE credit, you will not be able to change your CE certificate.
Full credit can only be claimed after completion of all required components.
Hardware/Software Requirements
Computer or Other Internet-Enabled Device; Internet Connection; Browser.
Materials
None.
Prerequisites
None.
Format
This is a live, virtual course.
Need Assistance or Have Questions?
For assistance logging in, accessing content, purchasing or completing Continuing Education credits, or for other questions, please contact us at events@acmt.net or visit our FAQ page.
If you are in need of accessible learning accommodations, please contact events@acmt.net for additional assistance.
Continuing Education
2025 ACMT Psychedelics Seminar, Live Virtual Event
Please claim your continuing education credits within 30 days of the live event: November 17, 2025
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at events@acmt.net. If you have questions about this CE activity, please contact AKH Inc at bethany@akhcme.com
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 10.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: Credit being awarded: 10.0 ANCC contact hours.
Pharmacists: AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 10.0 contact hours.
Key:
Complete
Next
Failed
Available
Locked